Related Experiment Video
Updated: May 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Tailor-made strategy in HCV treatment]
Tsunamasa Watanabe1, Yasuhito Tanaka
1Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences.
Host genetic variations significantly impact Hepatitis C virus (HCV) infection outcomes and treatment responses. Genome-wide association studies reveal polymorphisms crucial for personalized HCV therapies.
Area of Science:
- Virology
- Genetics
- Hepatology
Context:
- Hepatitis C virus (HCV) infection is a major global health concern, leading to severe liver disease and cancer.
- Current treatments achieve limited success, with only about 50% of patients responding to pegylated interferon-alpha and ribavirin.
- Spontaneous viral clearance occurs in a minority of acute infections, suggesting host factors are involved.
Purpose:
- To review the current evidence linking host genetic variations to Hepatitis C clinical outcomes.
- To explore the role of genome-wide association studies (GWAS) in identifying these genetic factors.
- To discuss the implications for developing personalized therapies for chronic Hepatitis C.
Summary:
- Host genome variations play a critical role in Hepatitis C virus (HCV) infection progression and treatment efficacy.
- Genome-wide association studies (GWAS) have identified specific genetic polymorphisms associated with HCV infection outcomes and adverse effects.
- Understanding these host-pathogen interactions is key to improving treatment strategies.
Impact:
- Identifies host genetic factors influencing Hepatitis C outcomes, aiding in risk stratification.
- Highlights the potential for genotype-specific and personalized treatment approaches for chronic Hepatitis C.
- Advances the understanding of host-virus interactions in viral hepatitis, paving the way for novel therapeutic targets.
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Pharmaceutical Poisoning: Treatment Strategies
